Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|July 5, 2020
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysisLuca Cantini, Federica Pecci, Alberto Murrone, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 2020
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patientsLuca Cantini, Federica Pecci, Daan P Hurkmans, et al.
Chemical Science|June 14, 2021
Tryptophan scanning mutagenesis as a way to mimic the compound-bound state and probe the selectivity of allosteric inhibitors in cellsIsabelle R Taylor, Victoria A Assimon, Szu Yu Kuo, et al.
Scientific Reports|September 12, 2019
Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS studyGiovanni Fucà, Luigi Mariani, Salvatore Lo Vullo, et al.
Journal of Thoracic Disease|November 19, 2021
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesotheliomaAlbero Murrone, Luca Cantini, Federica Pecci, et al.
Expert Opinion on Therapeutic Targets|July 15, 2020
Prognostic relevance of programmed cell death protein 1/programmed death-ligand 1 pathway in thymic malignancies with combined immunohistochemical and biomolecular approachRossana Berardi, Gaia Goteri, Alessandro Brunelli, et al.
Critical Reviews in Oncology/Hematology|July 2, 2021
Exploring the role of respiratory microbiome in lung cancer: A systematic reviewFabiana Perrone, Lorenzo Belluomini, Marco Mazzotta, et al.
Journal of Thoracic Disease|January 15, 2021
The role of angiogenetic single-nucleotide polymorphisms in thymic malignancies and thymic benign lesionsRossana Berardi, Gaia Goteri, Silvia Pagliaretta, et al.
Journal of Clinical Medicine|April 3, 2021
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line PembrolizumabEdoardo Lenci, Luca Cantini, Federica Pecci, et al.
Frontiers in Oncology|December 7, 2020
High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone MetastasesMarta Laganà, Cristina Gurizzan, Elisa Roca, et al.
Pageof 7